12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioView, Abbott deal

The companies partnered to develop an automated scanning solution to detect rearrangements in genes encoding anaplastic lymphoma kinase (ALK) in patients with advanced non-small cell lung cancer (NSCLC). BioView will be responsible for expanding approval of its Duet Automated Scanner to include automated imaging and analysis of...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >